The condensation of the terminal carboxyl group of the deglucoteicoplanin (TD) with various substituted hydrazines produced hydrazide derivatives having different physico-chemical properties.
The condensation of the terminal carboxyl group of the deglucoteicoplanin (TD) with various substituted hydrazines produced hydrazide derivatives having different physico-chemical properties.
This chemical modification of the carboxyl function does not affect the ability ofteicoplanin antibiotics to interfere in bacterial cell-wall synthesis.
The antibacterial activity of deglucoteicoplanin hydrazides (V) were found to depend mostly on their ionic character. All the hydrazides were slightly more active than TDon Escherichia coli. Those possessing an additional basic group were more in vitro active than TD against Gram-negative microorganisms. In Experimental Streptococcus pyogenes septicemia in the mouse, basic hydrazides were more active than other derivatives whenadministered subcutaneously although they are as potentasTD.
The glycopeptide antibiotic teicoplanin (Targocid)1 '2) was recently introduced in some countries for the parenteral treatment of severe infections caused by aerobic and anaerobic Gram-positive bactera. [3] [4] Teicoplanin is a complex consisting of five major closely related fractors (CTA) differing in the AT-acyl chain linked with /?-D-glucosamine at position C-56. CTA also contains one a-D-mannoseand one TV-acetyl-jS-D-glucosamine at positions C-42 and C-34, respectively.5) All three sugars can be removed by acidic hydrolysis under selected conditions obtaining the related aglycone (deglucoteicoplanin: TD) ( Fig.   1 ). 6) Teicoplanin is very poorly absorbed when administered orally and is inactive in vitro against
Gram-negative organism. Our program of synthetic modifications of teicoplanin antibiotics7)8) is directed to extend the antibacterial activity against Gram-negative organism and also to improve the bioavailability after oral administration. There is much evidence that modifications of the terminal carboxyl group do not change the intrinsic capability of teicoplanin antibiotics to inhibit the biosynthesis of bacterial cell wall.7 '9) The ester derivatives of teicoplanin, previously synthesized,7) possessed good in vitro activity even if they showed a general reduction of the in vivo antibacterial activities probably related to a decreased water solubility caused by an increase in the lipophilic character of the derivatives.
Instead, the more hydrophilic and more water soluble Af63-carboxamide derivatives of teicoplanin antibiotics9) were found more potent in vitro and more active in vivo after systemic administration than the parent teicoplanins and some of them even slightly more effective by the oral route.
Proceeding on with this promising approach and following the same strategy, we replaced the amide with the similar but more hydrophilic hydrazide group. To verify the influence of such modification on the in vitro and in vivo antibacterial activity, a series ofN63-carboxylhydrazides ofTDhave been synthesized. Chemistry
The formation of carboxamides by condensation of amines with the carboxyl group of the teicoplanin antibiotics9* was accomplished in good yield with diphenylphosphoryl azide as the condensing agent.10) Conversely the same reagent proved to be ineffective for the synthesis of the carboxylhydrazides of TD described in this paper (Table 1) . These derivatives were prepared according to the methods outlined in Scheme1.
The 15-amino group of TD ( Fig. 1 ) was protected as N-terr-butyloxycarbonyl (iV-BOC)9) (Scheme 1, I) then the 63-carboxyl group was activated1 1] forming the cyanomethyl ester II by adding chloroacetonitrile to a solution of I dissolved in A^,iV-dimethylformamide containing KHCO3. CompoundsHI were obtained from II and hydrazines (Scheme 1, B) in ethanol at 50°C. By using methanol as the solvent the undesired trans esterification of the active ester was obtained. The alkaline conditions used for this reaction must be carefully controlled to avoid epimerization at position 3 of TD (Fig. 1) .12) In fact, reacting II with hydrazine, a mixture of Ilia and of the corresponding epimer Ilia' was obtained. The epimers of TD derivatives show a characteristic peak shape in reversed phase HPLC,a higher Rt and a lower solubility than the corresponding parent compounds. For these reasons they are easily monitored (HPLC) and eliminated by filtration from the reaction mixture. Pure Ilia was instead quantitatively prepared from II by reaction with hydrazine monoacetate. Reaction of II with methylhydrazine and ethylhydrazme oxalate, according to Method B, led only to the corresponding 1-substituted hydrazides Illb and IIIc. These last reactions were faster and more selective than that with hydrazine and did not form the corresponding epimers. Under the same reaction conditions 1,1-dimethylhydrazine and 1,2-dimethylhydrazine did not
react. This failure can be explained by the steric hindrance of the methyl groups. NOV. 1990 Hydrazides Ilia and Illb were transformed into derivatives IV (Scheme 1) according to Method C by reaction with proper aldehydes and ketones in the presence of NaCNBH3. Although the adopted procedure is common,the solvent varies from compoundto compound, utilizing preferably a mixture of organic solvent and water. In particular, the reaction of Ilia with propionaldehyde gave 2-propylhydrazide (IVe) in BuOH -H2O -AcOH and 2,2-dipropylhydrazide (IVf) in MeOH-AcOH while the reaction with formaldehyde led only to 2,2-dimethylhydrazide (IVh) in both solvents. The reaction of Illb with propionaldehyde gave only the mono alkyl IVg. The reaction intermediate Schiff bases were detected by HPLConly for compounds IVe and IVmand isolated as stable compounds with crotonaldehyde (IV!) and acetophenone (IVo). In the other cases the equilibrium -NH2 +C=O±*-N=C-is such that to Schiff base is detectable or this is hydrolyzed under the HPLCanalysis conditions. Adding NaCNBH3the equilibrium is forced to the right by reduction of the ONdouble bond. The two compounds isolated as Schiffbases IV1 and IVo, were stable to the reducing action ofNaCNBH3. Noattempts with other reducing agents were tried. The two hydrazides IVp and IVq, bearing an amino group on the side chain were synthesized by condensation of Ilia with 7V,7V-dimethylamino acetaldehyde according to Method C and by 7V-alkylation with 2-bromoethylamine hydrobromide, respectively (Method D).
Final products V (Table 1) , obtained by deprotection of IV with CF3COOH(TFA) at room temperature, were isolated as TFA salt.
All the hydrazides and their intermediates show a UVabsorption maximumat 280nmin MeOH and in acidic mediumlike the starting compoundTD.
The IR spectra are in accordance with the assigned structures. The *H NMRspectral data ofhydrazides V were compared with those assigned in the detailed analysis of the spectrum ofTD HC1.6) The spectra showed that both the hydrazidic and TDmoieties were present. The 15-H signal (see Fig. 1 ) of the reported derivatives is at 5.4ppm instead of4.6ppm6) because of the deshielding effect of the 15-NH3+ group confirming that hydrazides V are as TFA salts. Table 2 shows only the significative assignments of the hydrazide moieties and of those protons showing different chemical shifts with respect to starting TD.
Acid-base titration of hydrazides V in methyl cellosolve (MCS) -H2O (4 : 1) shows the presence of ionizable functions with the apparent constant values ranging between 6.4 and 6.7 attributable to the terminal amino group. The found values were similar to the value of 6.9 obtained for TD.12) The p^Mcs values of the hydrazide moiety are not detectable under these analytical conditions while the amino group at the end of the hydrazidic chain, as in Vp and Vq, shows a PKMCSin the range 7.5~8.5. It is not possible to calculate an exact value due to the partial overlapping with the titration curve of the phenolic groups ofTD.13)
Results and Discussion The rational for transforming the terminal carboxyl group into an hydrazide was to reduce the lipophilicity, to modify the ionization bahavior and to improve water solubility of TD which was chosen because it is a single product obtained fairly easily from the teicoplanin complex.
Compounds IV and V were tested for their in vitro antibacterial activity (MIC). The intermediates IV were found, as expected, poorly active.14) The antibacterial activities of V and of the parent compound TD are reported in Table 3 . The in vitro activities of hydrazides V are comparable to that of TDagainst Staphylococci and a The spectra were recorded at 40°C in DMSO-d6solution (internal standard; TMS, S 0.00ppm). Streptococci while some exhibit better activity against E. coll. Compounds Vp and Vq, bearing a further basic group, have a slightly broader spectrum than TD against Gram-negative showing also activities against Pseudomonas aeruginosa and Proteus vulgaris. The epimer compound Va' has significantly lost, as expected, the antibacterial activity because in this molecule the unique configuration of teicoplanin antibiotics is destroyed.12)
The in vivo efficacy of selected hydrazides V was determined in experimental septicemia in the mouse (Table 4) . As expected, taking into consideration amide derivatives previously prepared,9) the more basic compoundsVp and Vqshow a better in vivo activity with respect to other derivatives but similar to that of starting TD. The lipophilicity parameter of the non basic hydrazides, measured as Rt in reverse phase compounds carrying an amino group in addition to the hydrazide moiety. Also the in vivo activity is favorably influenced by the presence of a basic amino group. This effect was also previously verified in the amide derivatives of teicoplanin antibiotics.9) These results agree with the well known correlations15) between physico-chemical and pharmacokinetic properties. In fact, positively charged derivatives of teicoplanin antibiotics generally showed lower serum binding and better in vivo activities than parent compoundsand, moreover, activity against Gream-negative bacteria was obtained.
Experimental
Evaporation of solvents was carried out, after adding BuOHto prevent foaming with a rotary evaporator at 45°C under vacuum. All compounds IV were purified by reverse-phase column chromatography using silanized Silica gel 60 (0.06-0.2mm; Merck). HPLCwas applied to monitor reactions, chromatographic fractions, and purity of the compounds using a Hewlett-Packard 1084 equipped with a UV detector at 254nm and a Hibar Li-ChroCart packet with Li-Chrosorb RP-8 (150 x 4mm, 5 /an) column. Injection volume, 20jal; flow rate, 1 ml/minute; mobile phases: (A) CH3CN-0.02m aq NaH2PO4 (pH 4.7), 5:95; (B) CH3CN-0.02m aq NaH2PO4, 75:25; step gradients as follows: (1 Stop.
36.
Stop.
All compounds were analyzed for C, H, N, using samples previously dried at 140°C under N2 atmosphere. Weight loss was determined by thermogravimetric analysis (TGA) at 140°C and inorganic residue was determined after heating the samples at 900°C in O2 atmosphere. The analytical results were ±0.3% the theoretical values.
FAB-MS positive ion spectra were obtained on a Kratos MS-50 instrument fitted with a standard FAB source and a high-field magnet; the sample (10/imol) was dispersed in a few fi\ of 2-thioglycerol-diglycerol (1 : 1) matrix and bombarded with a 6~9KeVbeam of Xe atoms. The P^mcs values were determined potentiometrically in MCS-H2O(4: 1) solution. An excess of 0.01 n HC1in the same solvent mixture was added and the resulting solution was titrated with 0.01 n NaOH in the same solvent mixture. The IR spectra were obtained in a Nujol mull with a Perkin-Elmer 850 instrument. The *H NMR spectra were obtained with a Bruker instrument AM250 equipped with an Aspect 3000 console at 250 MHz. The spectra were recorded at 40°C in DMSO<4solution (internal standard TMS, <S 0.00ppm). NOV. 1990 MICwas determined using the 2-fold dilution method in a microtiter system. The media used were:
Todd-Hewitt broth (Difco) for Streptococci and Iso-Sensitest broth (Oxoid) for Staphylococci, Streptococcus faecalis and Gram-negative bacteria. The final inoculum was about 104 cfu/ml. MIC(expressed in jug/ml) was read as the lowest concentration which showed no visible growth after 1 8~24 hours incubation at 37°C.
Experimental septicemia was induced in male and female CD-I mice (Charles River; weight 18~22 g; group five mice/treatment) by intraperitoneal injection of about 105 cells of Streptococcus pyogenes C 203, a challenge corresponding to about 1 00 times the LD50infected animals. Mice were treated once immediately after infection by sc route. On the 7th day, the ED50 (infected animals), expressed in mg/kg, was calculated16) on the basis of the percentage of surviving mice at each dose.
MethodA 7V15-BOC-TD (I): Teicoplanin aglycone (TD) (7 g, 5.8 mmol) was dissolved in 150ml ofDMF at room temperature, and 2,4,5-trichlorophenyl tert-butyl carbonate (2.55 g, 8.5 mmol) and triethylamine (TEA) (1. 1 ml) were added. The reaction mixture was stirred at 40°C overnight. The solvent was evaporated under reduced pressure at 50°C, and the residue obtained was dissolved in BuOH-EtOAc (2 : 1), washed with acid water (pH 3) and then washed twice with distilled water. The solvent was removed under reduced pressure and the resulting concentrated solution (about 30ml) was diluted with 600ml of ethyl ether. A solid was separated and collected by filtration and washed with ethyl ether, yielding 5.5 g of compound I (HPLC (2), Rt 12.3 minutes). N15-BOC-TDCyanomethyl Ester (II): Chloroacetonitrile (1 ml) was added to a solution of I (3 g, 2.3mmol) in 25ml of DMFcontaining KHCO3(450mg). The reaction was stirred for about 3 hours at room temperature after which a second measure of C1CH2CN (0.5 ml) was added and stirring continued for a further 3 hours. Whenthe reaction was considered terminated (HPLCassay), the reaction mixture was worked up by diluting it with ethyl ether (200ml). The solid which formed was collected and dried yielding 3 g of crude II that was used as such in the next reactions. IR vmax (Nujol) cm" * 1755 (CO) (HPLC (2), Rt 23.6 minutes).
Preparation of N15-BOCHydrazides III and IV
Method B TV15-BOC-TDHydrazide (Ilia): To a solution ofII (10 g, 7.55 mmol) in 500ml ofabs EtOH, CH3COOH (4.3ml, 75mmol) and NH2NH2H2O (3.7ml, 76mmol) were added. The reaction mixture was stirred at room temperature for 12 hours, then a second measure ofCH3COOH (0.21 ml) and hydrazine monohydrate (0.185 ml) was added and the reaction continued for 3 hours. The solvent was evaporated under reduced pressure. The residue was diluted with water (200 ml) and the pH corrected to 3 with 1 n HC1 and extracted with 500ml BuOHand 200ml of EtOAc. The organic layer, was washed three times with water, concentrated to 60ml and then it was diluted with 350ml of ether. After chilling the suspension for about 1 hour, the precipitate was filtered, washed with ether and dried under vacuum overnight yielding 8.2g of the title compound (HPLC (2), Rt 15.6minutes).
N15-BOC-TD Hydrazide Epimer (Ilia'):
A solution of II (1 g, 0.75mmol) in 30ml of abs EtOH was added with 5ml of NH2NH2à"H2O and the cloudy solution which formed was stirred at 40°C for 3 hours. The reaction HPLCprofile showed the corresponding peak of compound Ilia (40%) and a new peak with a higher Rt (Ilia', 60%). The solvent was removed under vacuumand the residue, suspended in water, was filtered and then dissolved in a minimumamount of a mixture of H2O-CH3CN (1 : 1). The resulting solution was applied at the top of a chromatographic column prepared with lOOgof silanized silica gel, pre-equilibrated with 150ml of 1% aq HCOONH4 at pH 5 and stabilized with 200ml of a mixture H2O-CH3CN(9 : 1). The column was washed with 150 ml of the same mixture, and then developed with a stepwise gradient from 10 to 50%of CH3CNin H2O. Fractions of about 10ml each were collected and assayed by HPLC. Fractions containing the desired compound were pooled, BuOHwas added and the solution evaporated under vacuum. The residue was treated with ethyl ether, filtered and dried over P2O5 yielding 400mg of the title compound (HPLC (2) hydrazine (1 ml) was added and the reaction continued for 1 hour. The mixture was then concentrated to about 10ml under reduced pressure and ethyl ether (100ml) was added. A precipitate formed which was filtered, dissolved in the minimum amount of a mixture of H2O-CH3CN(1 : 1) and chromatographed on silanized silica gel as reported. Fractions containing the pure product (HPLCarea > 92%) were worked up as usual, yielding 320mg of the title compound (HPLC (2), Rt 17.7 minutes).
7V15-BOC-TD1-Ethylhydrazide (IIIc): To a solution of II (1 g, 0.7mmol) in 100 ml of abs EtOH, ethylhydrazine oxalate (115mg, 1.15mmol) and TEA (0.3mg, 2.3mmol) were added. The mixture was stirred at 50°C for 4 hours after which it was worked up and purified, as in the previous example, yielding 250mg ofIIIc (HPLC (2), Rt 18.5 minutes).
MethodC iV15-BOC-TD2-Benzylhydrazide (IVd): To a solution of compound Ilia (1.5 g, 1.1 mmol) in a mixture of CH3COOH(22 ml) and MeOH(1 1 ml), benzaldehyde (1.5 ml) and a catalytic amout of/?-toluensulfonic acid (l mg) were added. After about 15 minutes of stirring at room temperature, the HPLCanalysis (gradient profile 2) showed a peak at Rt 25.5 minutes (2-benzylidenehydrazide derivative). Two portions of NaCNBH3(0.5 g each) were then added at 20minute intervals. The compound with Rt 25.5 minutes completely transformed into a compoundhaving Rt 24.2 minutes. The solvent was removed under reduced pressure, then the residue was treated with distilled water (50 ml) and the solid which formed was filtered. The wet crude material was suspended in CH3CN-H2O (7 : 3) and mixed with silanized silica gel (10g); after removing the solvents under reduced pressure, the solid was loaded on the top of a chromatographic column containing 120g of the same silica gel prepared with a 10%CH3CNin H2O. Impurities were removed by eluting with CH3CN-H2O (3 : 7), then the compound having Rt 24.2 minutes was eluted with a linear gradient from 40 to 60%CH3CNin H2O. Fractions containing the pure compound were pooled, BuOHwas added and the solvents removed under vacuum. The residue, treated with ethyl ether was filtered and dried, yielding 500mg of the title compound (HPLC (2), Rt 24.2 minutes).
iV15-BOC-TD2-Propylhydrazide (IVe): A solution of Ilia (0.7 g, 0.5 mmol) was added to a mixture of BuOH (60ml), H2O (5.5 ml), CH3COOH(1.2ml) and propionic aldehyde (0.6 ml, 8.33 mmol). The mixture was stirred for 20 minutes at room temperature then a second portion of aldehyde (0.6 ml) was added and the reaction continued for 1 hour. HPLCanalysis (program 2) showed the starting material (Ilia, Rt 15.6 minutes) and its SchifT base (Rt 18.78 minutes) with a ratio in the range 30 : 70, respectively. NaCNBH3 (0.5 g) was added under stirring at 25°C internal temperature. Aftet 2 hours a second measure of propionic aldehyde (0.6ml) was added and the reaction continued for 1 hour. NaCNBH3(0.3 g) was then added and stirring was continued until disappearance of the starting material. Thereafter the reaction mixture was acidified by adding diluted hydrochloric acid. The precipitate which formed was collected by filtration, dissolved in a mixture of H2O-CH3CN (7 : 3), loaded on a column of silanized silica gel and eluted with a linear gradient from 30 to 65% of CH3CNin H2O. Working up fractions containing the pure compound, 330mg of the title compound was obtained (HPLC (2), Rt 18.8 minutes).
7V15-BOC-TD 2,2-Dipropylhydrazide (IVf): To a solution of Ilia (1.2g, 0.9mmol) in MeOH(30ml) and CH3COOH(15ml), propionaldehyde (1.5ml, 20.7mmol ) and /?-toluensulfonic acid (1.2mg) were added. The mixture was stirred at room temperature for 30 minutes, and then NaCNBH3 (0.5 g, 7.9 mmol) was added. After about 2 hours of reaction the reaction was adjusted to pH 2 by adding 1 n HC1and the solvent was evaporated under reduced pressure. The residue, dissolved in a mixture of CH3CN-H2O(2 : 3) was loaded on a chromatographic column of silanized silica gel (150g) and eluted with 25% CH3CNin water (500ml) and then with a linear gradient from 25 to 40% of CH3CNin water. Fractions containing the pure compound were pooled, evaporated and treated with ethyl ether. The precipitated solid was collected and dried at 50°C under reduced pressure yielding 550 mg of title compound (HPLC (2), Rt 22.9 minutes).
N1 5-BOC-TD l-Methyl-2-propylhydrazide (IVg): To a solution ofmethylhydrazide Illb (2 g, 1.5 mmol) in 60ml of MeOH, propionaldehyde (1.5ml, 20.7mmol ) and p-toluensulfonic acid (15mg) were added and the mixture stirred at room temperature for 2 hours. The NaBH4(100mg, pellets) was added and the reaction continued overnight. The solvent was removed under reduced pressure and the residue, suspended in 40ml of water at pH 4, was purified by column chromatography as previously reported. Working up the fractions containing pure compound, 320mg of IVg was obtained (HPLC (2), Rt 10.4 NOV. 1990 minutes).
AT15-BOC-TD 2,2-Dimethylhydrazide (IVh): A 40% aq HCHO(1.2ml) was added to a solution of hydrazide Ilia (1.2g, 0.9mmol) in 72ml of CH3CN.The mixture was stirred at room temperature for 15 minutes, and then two portions of NaCNBH3 (lOO mg) were added at 2 hourly intervals. The reaction was continued overnight, then the organic solvent was removed under reduced pressure and the residue diluted v/ith 50ml of water. The suspension was adjusted to pH 3 with 1 n HC1and the product extracted with BuOH(100 ml). The organic layer was washed with water (30 ml) and evaporated under reduced pressure. The residue was treated with EtOAc, filtered, washed with ethyl ether and dried under vacuum, yielding 800mg ofIVh (HPLC (2), Rt 16.3 minutes).
To a solution of hydrazide Ilia (1.2g, 0.9 mmol) in BuOH (120 ml) and H2O (100 ml), D,L-glyceraldehyde (600 mg, 6.6 mmol) and/?-toluensulfonic acid (60mg) were added. The reaction was stirred at room temperature for 20 minutes, then NaCNBH3 (300mg, 127mmol) was added and the reaction continued. After 2 hours, a second measure of D,L-glyceraldehyde (600 mg) was added and followed after 30 minutes by NaCNBH3(700 mg). Stirring was continued for 3 hours and then the pH was adjusted to 8 with NaHCO3.Ethyl acetate (50ml) was added and the mixture was washed with water (40ml x three times). The organic solvent was removed under reduced pressure and the residue was mixed with Celite (a filter aid) and loaded on a chromatographic column prepared with 150g of silanized silica gel in H2O-CH3CN (9 : 1). This column was eluted with 1 liter of 30% aq CH3CNand then with 1 liter of40% aq CH3CN.Fractions containing pure product were collected and worked up as previously reported, yielding 600mg of title compound (HPLC (2), Rt 15.1 minutes). N15-BOC-TD2-(2-Butenylidene)hydrazide (IVI): To a solution of hydrazide Ilia (1.2 g, 0.9 mmol) in CH3CN(72ml) and H2O(10ml), 0.6ml ofcrotonaldehyde (7.3 mmol) was added. The solution was stirred at room temperature for 15 minutes then NaCNBH3 (lOOmg) was added followed by a second measure after 1 hour and stirring continued for 3 hours. The solvent was removed, water (80ml) was added and the resulting mixture was adjusted to pH 3 with 1 n HC1and extracted with 200ml of BuOH-EtOAc (3 : 1). The organic layer was washed with 30ml of water and evaporated under reduced pressure. The residue was suspended in EtOAc, filtered and washed with ethyl ether, yielding 1.2 g of title compound (HPLC (2), Rt 20.8 minutes).
N15-BOC-TD2-Cyclopentylhydrazide (IVm): To a solution of hydrazide Ilia (1.2g, 0.9 mmol) in 60ml of BuOH, 10ml of H2Ocyclopentanone (1 ml, 1 1.3 mmol) and /?-toluensulfonic acid (25mg) were added. The mixture was stirred at room temperature for 1 hour. The HPLCanalysis (gradient profile 2) showed the formation of the corresponding Schiff base (Rt 19.5minutes). NaCNBH3 (1 g) was added in small amounts during 1 hour. A second measure of cyclopentanone (0.2ml) was added followed after 30 minutes by an additional amount of NaCNBH3 (100mg). The reaction was continued for 3 hours, the solvent was then removed and the residue purified by column chromatography on silanized silica gel with a linear gradient from 25 to 40% of CH3CNin water. Working up fractions containing pure product 600mg of title compound was obtained (HPLC (2), Rt 20.5 minutes). N1 5-BOC-TD2-/(1 ,3-Dimethyl)butyl/hydrazide (IVn): To a solution ofhydrazide Ilia (1.2 g, 0.9 mmol) in 108ml of BuOHand 12ml of H2O, methyl isobutylketone (1.2ml, 9.6 mmol) was added. The solution was stirred at room temperature for l hour, then NaCNBH3(0.8g) was added. After 2 hours, EtOAc (30ml) was added and the organic phase separated, washed with water (50ml) and evaporated under reduced pressure. The residue was treated with 10ml of EtOAc and diluted with 100ml of ethyl ether. The solid which separated was filtered washed with Et2O and dried under vacuum, yielding 650 mg of IVn (HPLC (2), Rt 23.2 minutes). N15-BOC-TD 2-(l-Phenylethylidene)hydrazide (IVo): To a solution of 1.2 g (0.9 mmol) of hydrazide Ilia in 140ml of BuOHand 12ml of H2O, acetophenone (1.2ml, 10 mmol) was added and the solution was allowed to stand for 2 hours at room temperature. Solvents were evaporated under reduced pressure and the crude material was purified on a silica gel column eluting with abs EtOH. Fractions containing pure product were pooled, evaporated and the residue taken up with Et2O, collected by filtration and dried under reduced pressure, yielding 0.9mg of IVo (HPLC (2) (obtained from dimethylamino acetaldehyde diethylacetal)17) and CH3COONa(246 mg, 3 mmol) were added under nitrogen. The mixture was stirred at room temperature for 1 hour, then NaCNBH3 (30mg, 0.4 mmol) was added. After 2 hours, a second measure of the same aldehyde (200 mg) was added followed, after 1 hour, by 30mg of NaCNBH3. The reaction was continued overnight then the pH adjusted to 3 with 1 n HC1and the solvent evaporated under reduced pressure. The residue was purified on a silanized silica gel (150g) chromatographic column developed with a linear gradient from 25 to 60% of CH3CN in water, yielding 500mg of title compound (HPLC (2), Rt 21.3 minutes).
MethodD N15~BOC-TD2-(2-Aminoethyl)hydrazide (IVq): To a solution of hydrazide Ilia (1. 15 g, 0.89 mmol) in DMF(70ml), Br(CH2)2NH2 HBr (0.2g, 0.9mmol) was added. The reaction was maintained at 50°C for 4 hours and then a second portion of bromoethylamine (0.2g) was added followed, after 2 hours, by TEA(150ml, 1.07mmol). The reaction was continued overnight at room temperature (HPLCanalysis showed a 70%transformation). The crude material, after solvent evaporation under reduced pressure, was dissolved in the minimum amount of a mixture CH3CN-H2O (3 :7) and loaded on the top of a column containing 150 g of silanized silica gel. The column was eluted with a linear gradient from 20 to 35 % ofCH3CNin H2O. Fractions containing the desired compound were combined, the solvent evaporated to dryness and the solid, treated with Et2O, was filtered off and dried under vacuum, yielding 350mg of IVq (HPLC (2), Rt 20.8 minutes).
Preparation of Hydrazides V Method E
The BOCprotective group of all hydrazides III and IV was removed according to the procedure reported here: EX: CF3COOH(4ml) was dropped into a suspension of a purified N15-BOC-TD hydrazide (1 mmol) in 20ml of CH2C12and 10°C. The resulting solution was stirred for 15minutes at room temperature then Et2O was added and the solid which formed was filtered, washed with Et2O and dried under vacuum yielding the hydrazide V as mono-trifluoro acetate salt (Vp and Vq were obtained as di-trifluoro acetate salts).
